Actavis is pleased to announce the launch of Memantine Tablets (Nemdatine) Treatment Initiation Pack to complement the products already included within the Actavis portfolio.
Memantine Tablets (Nemdatine) are used to treat adult patients with moderate to severe Alzheimer’s disease. The treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s disease.
Memantine Tablets (Nemdatine) Treatment Initiation Pack contains 28 film-coated tablets and is presented with four packets: 5mg x 7, 10mg x 7, 15mg x 7, 20mg x 7. The existing range of products in the Actavis portfolio includes: Memantine Tablets (Nemdatine) 10mg x 28, 10mg x 56 and 20mg x 28; Memantine Oral Solution 10mg/ml 50ml and 100ml.
Jonathan Wilson, Managing Director of Actavis UK comments: "We continue to expand our portfolio of generic medicines looking for innovation which will increase patient safety and ease-of-use.
Currently we can satisfy over 85% of pharmacists’ Category M dispensing needs, ensuring patients receive the medications they need when they need them. The extensive range of products in the Actavis UK portfolio is accessible through the Actavis Scheme which features net pricing and a simple three-tier discount band model which offers market-competitive prices to pharmacists, enabling them to focus more of their time on serving the health needs of their community."
For further information, please contact the Actavis press office:
Louise Stone, Havas PR
020 7467 9230